期刊文献+

清远地区大肠埃希菌ESBLs的检测及其对20种抗生素的耐药性与治疗策略 被引量:4

Examination,Resistance to 20 Antibiotics and Therapeutic Countermeasures of Escherichia Coil Producing Extended Spectrum Beta Lactamases in Qingyuan Region
暂未订购
导出
摘要 目的 观察清远市地区产超广谱 β-内酰胺酶 (ESBL s)大肠埃希菌的耐药性和流行情况 ,指导临床用药。方法 应用 Micro Scan Auto SCAN- 4、专用 NC2 1鉴定板检测 180例大肠埃希菌 ESBL s的产生和其体外对抗生素的耐药性。结果 产 ESBL s大肠埃希菌阳性率 5 1.1% ,以儿科 (10 0 % )最高、重症监护病房 (81.8% )次之 ,对头孢菌素类、氨苄西林、哌拉西林、环丙沙星、妥布霉素、复方新诺明呈多重耐药、耐药率 42 .4%~ 91.3% ,显著高于非产 ESBL s大肠埃希菌 (P<0 .0 5~ 0 .0 1) ;对亚胺培南、哌拉西林 /三唑巴坦具有高敏感性。结论 清远地区具有较高的产 ESBL s大肠埃希菌检出率 ,对于产 ESBL s大肠埃希菌应用亚胺培南、哌拉西林 /三唑巴坦等含 Objective To observe the resistance and the prevalence of Escherichia coil strains producing Extended Spectrum β lactamases(ESBLs) in Qingyuan region in order to pave the way for clinical correct use of drugs.Methods 180 Escherichia coils were examined whether producing ESBLs or not and antibiotic resistance tests in vivtro were performed by NC 21 board of MicroScan AutoSCAN 4.Results The ESBLs positive rate was 51.1% with departmemt of pediatric(100%) and ICU(81.8%) being the top two.The ESBLs producing strains showed resistance to tocephalosporins,ampicillin,piperacillin,ciprofloxacin,tobiamycin,trimethoprim/sultamethoxazole with rates ranging from 42.4%~91.3%,significantly higher than strains not producing ESBLs(P<0.05~0.01).ESBLs producing strains showed high susceptivity to imipenem and piperacillin/tazobac.Conclusions The isolating rate of ESBLs producing Escherichia coil strains in Qingyuan region was pretty high.Combined antibiotics containing β Lactama/β Lactamase inhibitor such as imipenem,piperacillin/tazobac were effective to ESBLs producing Escherichia coil strains.
出处 《中国误诊学杂志》 CAS 2002年第2期194-196,共3页 Chinese Journal of Misdiagnostics
关键词 大肠杆菌 微生物检测 革兰氏阴性菌 β-内酰胺酶内 微生物抗药性 抗生素 Escherichia coli/enzymology Gram negative bacteria/enymology beta Lactamases/analysis Drug resistance,microbial
  • 相关文献

参考文献9

二级参考文献26

  • 1National Committee for ClinicalLaboratory Standards.Peformance standards for antimicrobial susceptibility testing;ninthinformation.Standard M100-S9.Pennsylvania[S]:NCCLS,1999.1-103
  • 2Shehabi AA,Mahafzah A,Baadran L,et al.High incidence of Klebsiella pneumoniaeclinical isolates to extendrd-spectrum β-lactam drug in intensive caieuntis[J].Diagnostic Microbiology and Infectious Disease.2000,36(1):53-56
  • 3张秀珍,王辉,胡云健,谢秀丽,徐英春,陈民钧,周贵民,吴坚,许淑珍,张淑兰,王清涛,杜小玲.北京五家医院5374株菌对18种抗生素的敏感性[J].中华医学杂志,1997,77(7):543-544. 被引量:26
  • 4Babini GS,Livermore DM. Journal of Antimicrobial Chemotherapy . 2000
  • 5Gregersen N,Van Nierop W,Von Gottberg A,etal. Pediatric Infectious Disease . 1999
  • 6Knox JR. Antimicrobial Agents and Chemotherapy . 1995
  • 7Schiappa DA,Hayden MK,Matuchek MG,et al. The Journal of Infectious Diseases . 1996
  • 8George Jacoby GA. Clinical Infectious Diseases . 1998
  • 9Lucet JC,Chevret S,Decre D,et al. Clinical Infectious Diseases . 1996
  • 10Jacobson KL,Cohen SH,Inciardi JF,et al. Clinical Infectious Diseases . 1995

共引文献487

同被引文献25

  • 1卢月梅,何林,张阮章,穆雪鵾,陈升汶.产CTX-M型超广谱β-内酰胺酶菌株的药敏试验结果分析[J].中国误诊学杂志,2004,4(7):994-996. 被引量:4
  • 2曾贱高,刘利辉,张华,李龙平.1 055株革兰阴性杆菌菌种分布及耐药性分析[J].中国感染控制杂志,2006,5(1):62-64. 被引量:23
  • 3JACOBY G A,HAN P.Detection of extended-spectrum beta-lactamases incliical isolates of Klebsiella pneumoniae and Escherichia coil[J].J Clin Microbiol,1996,34:908-910.
  • 4Baraniak A, Fiett J, Sulikowska A, et al. Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland[J].Antimicrob Agents Chemother,2002,46(1):151-159.
  • 5Bauernfeind A,Grimm H,Schweighart S.A new plasmidic cefotaximase in a clinical isolate of Escherichia coli[J].Infection,1990,18(1):294-298.
  • 6Jsambrook Effritsch Tmaniatis.分子克隆实验指南[M](第2版)[M].北京:科学出版社,1999.19-21.
  • 7Carsenti E H, Cavallo J D, Roger P M, et al. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginoas[J]. Clin Microbiol Infect, 2001,7(3): 144 - 147.
  • 8National Committee of Clinical Laboratoy Standards. 2004 24. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement. NCCLS document M100 - S14. Wayne Pennsylvania[S]. NCCLS, 2004,1 - 159.
  • 9Ramphal R,Ambrose P G. Extended-spectrum beta-lactamases and clinical outcomes:current date[J]. Clin Infect Dis, 2006, 42(Suppl 4) :S164 - 172.
  • 10Goossens H,Grabein B. Prevalence and antimicrobial suseeptiblity data for extended-spectrum beta-lactamase and AmpCproducing Enterobaeteriaceae from the MYSTIC Program in Europe and the United States (1997- 2004)[J]. Diagn Microbiol Infect Dis,2005, 53: 257-264.

引证文献4

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部